Yu Jonathan Yen-Wen sold $22K of IRON

Yu Jonathan Yen-Wen (Chief Operating Officer) sold 300 shares of Disc Medicine, Inc. (IRON) at $72.50 on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yu Jonathan Yen-Wen
Published Jun 30, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IRON
Neutral
high confidence
Mentioned
$IRON
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRONNeutralLow
01

Why it matters

This provides transparency on officer trading activity but does not introduce new company performance, product, or regulatory information.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but the pre-arranged nature and small size limit decision impact.

03

What to watch

The sale size is modest (300 shares) and the plan is pre-arranged, which reduces interpretability versus unscheduled sales.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-30; transaction dated 2026-06-26.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Disc Medicine, Inc. (IRON).

Company-level read

Ticker impact

$IRONNeutralHigh confidence
Context

Disc Medicine COO Yu Jonathan Yen-Wen sold 300 shares in an open-market transaction at $72.50 on 2026-06-26 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction would be short-lived.

Evidence & confidence

The filing is a small, pre-planned open-market sale by an officer; it does not disclose new fundamentals, guidance, or regulatory/operational events.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated officer selling can coincide with internal risk management; traders may still watch for follow-on sales or changes in trading patterns.

Key entities

  • Disc Medicine, Inc.

    Company whose insider transaction is disclosed via SEC Form 4.

  • Yu Jonathan Yen-Wen

    Chief Operating Officer who sold 300 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IRONHighAI 9/10

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update • Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints • Bitopertin NDA resubmission planned by e

$IRONHighAI 9/10

Disc Medicine, Inc. (IRON): Results of Operations and Financial Condition

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants October 19, 2026 WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on

$IRONHighAI 8/10

Why is Disc Medicine stock sliding today?

Disc Medicine (IRON) stock fell 1.0% in pre-market trading after pricing a $450M public offering of 6M shares at $75 each, a discount to recent prices. The offering, with potential for additional shares, may dilute existing holders. Proceeds will fund clinical development and general corporate purposes. Analysts recently raised price targets following positive trial results, but insiders have been net sellers.